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Background: HIV-1 Drug Resistance Mutations (DRMs) among
individuals with Immunological failure (IF) on different NRTI
based ﬁrst-line regimen, Thymidine analogue (TA) - AZT & D4T
and Non-Thymidine Analogue (NTA) -TDF; and predict viral drug
sucessibility to gain vision about optimal treatment strategies for
second-line.
Methods & Materials: Cross-sectionaly, 400 HIV-1 infected
patients, failingﬁrst-lineHAARTwere included in the analysis. HIV-
1 pol gene spanning 20 – 240 codons of Reverse Transcriptase was
genotyped by validated homebrew method and mutation pattern
was examined, (IAS-USA 2014 and Stanford HIV drug resistance
database v7.0)
Results: Out of 400, majority had subtype C infection 97.2%
(n=389) and any DRM was seen in n=379. On analyzing two
groups, duration of failure was longer for TA (n=279), with the
median of 57.6 (IQR 35.2-76.2) months compared to NTA (n=121),
24 (IQR 11.2-51.8) months, (p <0.05). Among individual mutation
analyzed K65R (23.2% vs. 4.6%), L74V (10.7% vs. 0.3%) and Y115F
(11.6% vs. 0.7%) was signiﬁcantly higher among NTA compared to
TA, (p <0.001); whereas M184V and TAM accumulation was sig-
niﬁcantly high in TA (p<0.05), Among NNRTI mutation K101E/P/H
(18.1% vs. 8.5%), G190A (32.7% vs. 27.6%) was higher among NVP
(p<0.05) and K103N (57% vs. 35.1%), V106M (30.2% vs. 12.1%) was
higher among EFV (p<0.05).
Based on themutation pattern observed in both groups,we ana-
lyzed the impact ofDRMson future therapyand foundas; in TAhigh
level of resistance was observed to all drugs, except TDF (71.5%)
>AZT (56.3%) >ABC (50%). In the same way among NTA AZT (78.6%)
>TDF (63.7%) and >ABC (38.1%) was observed. On combining both,
among TA failures still 56.7% and 71.4% can be considered for AZT
andTDFbased second-line. Similarly, amongNTA failures still 63.7%
and 78.6% can be considered for TDF and AZT based second-line
regimen.
Conclusion: As expected TA based ﬁrst-line failure had devel-
oped more cross resistance compared to NTA group, but still
majority can be recycled in the same regimen as second-line
option. Further, in resource limited settings, treatment outcome
is monitored immunologically; when virological based treatment
monitoring comes in practice further emergence of DRMs can be
avoided by early switching.
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The impact of HIV infection on the burden and
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Background: The impact of HIV infection on the incidence and
severity of inﬂuenza illness in adults in sub-Saharan Africa (SSA)
is unclear. Although annual seasonal inﬂuenza vaccination is rec-
ommended for HIV-infected persons in developed settings, it is not
part of routine HIV care in SSA.
Methods & Materials: At the Queen Elizabeth Central Hospital
in Blantyre, Malawi, we conducted: i) a prospective cohort study,
to compare the incidence of inﬂuenza illness betweenHIV-infected
and HIV-uninfected adults; ii) a case control study, to determine
risk factors for severe inﬂuenza presentation. Cases were adults
with severe inﬂuenza illness (lower respiratory tract infection
(LRTI) requiring hospitalization). Controls were adults with mild
inﬂuenza presentation (inﬂuenza-like illness (ILI) managed as out-
patients). Inﬂuenzawas identiﬁed fromnasopharyngeal specimens
by real-time reverse transcription polymerase chain reactions (RT-
PCR).
Results: The cohort study enrolled 360 HIV-infected (median
CD4 count 390 cells/cm3) and 248 HIV-uninfected adults, pro-
viding 520 and 348 person-years of observation, respectively.
Between April 2013 and March 2015, 24/229 (10.5%) ILI episodes
in HIV-infected and 5/119 (4.2%) in HIV-uninfected adults were
inﬂuenza PCR-positive. HIV-infected adults had almost three times
increased risk of laboratory-conﬁrmed inﬂuenza illness compared
to HIV-uninfected adults (incidence rates 46.0 vs. 14.5 per 1000
person-years; incidence rate ratio 2.75, 95% conﬁdence interval (CI)
1.02-7.44). In the case control study, 56/518 (10.8%) patients with
hospitalised LRTI, and 88/642 (13.7%) with ILI were inﬂuenza PCR-
positive. HIV prevalence among the inﬂuenza-positive cases and
controls were 70% and 30% respectively. On multivariable analy-
sis, HIV infection was the most important risk factor for severe
inﬂuenza presentations (odds ratio (OR) 4.98, 95%CI 2.09-11.88),
